Skip to main content
. Author manuscript; available in PMC: 2014 Jun 15.
Published in final edited form as: J Immunol. 2013 May 17;190(12):6259–6268. doi: 10.4049/jimmunol.1203539

Figure 1. Clinically relevant doses of temozolomide inhibit T lymphocyte proliferation in mice.

Figure 1

(A) C57BL/6 mice (n=3 per group) were treated with the indicated dosages of TMZ daily for 5 days and 2 days after the last dose mice were sacrificed and splenocytes plated with CD3/CD28 beads and IL-2. Viable cell counts were assessed at the indicated time points. Representative of two independent experiments. Error bars indicate SEM. *, p<0.05; **, p<0.01. (B) Purified CD8 T cells from mice treated with the indicated dosages of TMZ (n=3 per group) were stimulated as above. Viable cell counts were assessed at the indicated time points. Data are pooled from two independent experiments. Error bars indicate SEM. ***, p<0.001. (C) Aliquots of CD8 T cells stimulated as in (B) were taken for FACS analysis of phosphorylated ATM on day 4 post-stimulation.